| 刘国东 李欣 孟伟旭 任翔 李嘉航.TP新辅助化疗方案治疗Ib-Ⅱa期局部晚期宫颈癌的临床效果观察[J].,2014,14(12):2267-2270 |
| TP新辅助化疗方案治疗Ib-Ⅱa期局部晚期宫颈癌的临床效果观察 |
| Clinical Efficacy of Neoadjuvant Chemotherapy with TP Scheme inTreatment of Local late Stage Ib-Ⅱa Cervical Cancer |
| |
| DOI： |
| 中文关键词: 宫颈癌 新辅助化疗 顺铂 紫杉醇 疗效 |
| 英文关键词: Cervical cancer Neoadjuvant chemotherapy Cisplatin Paclitaxel Clinical efficacy |
| 基金项目:国家自然科学基金项目(30872464) |
|
| 摘要点击次数: 709 |
| 全文下载次数: 1251 |
| 中文摘要: |
| 目的：观察并探讨宫颈癌术前行TP 与PF 两种新辅助化疗方案的临床效果，优选新辅助化疗方案。方法：将2008 年1 月
-2010 年12 月间入选的91 例Ib-Ⅱa 宫颈癌患者随机分为A（n=46）、B(n=45)两组,A 组患者子宫切除术前予TP 新辅助化疗方案，
B 组予PF 方案，各2 个周期，对比化疗结束后两组临床疗效、化疗期间药物毒性反应及术后2 年内宫颈癌复发率。结果：①A、B
两组总体有效率分别为89.1%、82.2%，差异不具有统计学意义（P＞0.05），但前者化疗后瘤体直径明显小于B 组(P＜0.05)；②两
组药物毒性反应构成不具有统计学差异（P＞0.05），但A 组胃肠道反应与肝脏毒性发生率明显低于B 组(P＜0.05)；③A、B 两组
组术后2 年内宫颈癌复发率分别为2.2%、11.9%，复发率无统计学差异（P＞0.05）。结论：宫颈癌术前TP 新辅助化疗方案较之BIP
方案具有比较优势，更具备临床推广价值。 |
| 英文摘要: |
| Objective:The paper is to investigate and explore the clinical effect of cervical cancer underwent TP or PF two kinds
of neoadjuvant chemotherapy (NACT), and to prefer the better neoadjuvant chemotherapy scheme.Methods:91 cases from Jan.2008 to
Dec.2010 were randomized divided into A (n=46)& B(n=45) group, group A was given TP (DDP +TAX) NACT scheme before radical
hysterectomy,group B was given PF (DDP+5-Fu) scheme, and each with 2 treatment cycles, comparison on clinical effect after NACT,
drug toxicity and recurrence rate within 2 years after hysterectomy were conducted between 2 groups.Results:①0verall efficiency of A,
B group were 89.1%, 82.2%respectively, the difference was not statistically significant (P>0.05), but the diameter of tumor of group A
after chemotherapy was significantly less than that of groupB (P<0.05); ②Constitution of drug toxicity of 2 groups was not statistically
different (P>0.05), but the incidence rate of gastrointestinal reaction &liver toxicity of group A was significantly lower than that of group
B (P<0.05); ③Recurrence rates ofA & B group within 2 years after surgery were 2.2%, 11.9%respectively, also with no significant difference
(P>0.05).Conclusion:Neoadjuvant chemotherapy of TP scheme compared with BIP scheme has comparative advantage, and
have more clinical value of popularization. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
